Jason B O'Connor

US Patent:

20090143732, Jun 4, 2009

Filed:

Nov 29, 2007

Appl. No.:

11/947117

Inventors:

Jason B. O'Connor - South Boston MA, US
Luis Malave - Reading MA, US

Assignee:

INSULET CORPORATION - Bedford MA

International Classification:

A61M 5/142

US Classification:

604151

Abstract:

A prefilled syringe may be interfaced with and used to fill an infusion pump with therapeutic liquid. The dispensing end of the prefilled syringe may be coupled (either directly or indirectly using a syringe cap) to a syringe coupling region of the infusion pump, for example, using a threaded engagement or snap fit engagement. As the dispensing end of the prefilled syringe is coupled to the syringe coupling region of the pump housing, a needle passes through the pump housing and/or a needle passage region of the dispensing end such that the prefilled syringe is fluidly coupled to a reservoir in the pump. In various embodiments, the needle may be located in the syringe coupling region or in a syringe cap coupled to the dispensing end of the prefilled syringe.

US Patent:

20220379028, Dec 1, 2022

Filed:

Aug 9, 2022

Appl. No.:

17/818504

Inventors:

- Acton MA, US
Yibin ZHENG - Hartland WI, US
Jason O'CONNOR - Acton MA, US

International Classification:

A61M 5/172
G16H 40/63
A61K 38/28
A61M 31/00

Abstract:

Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

US Patent:

20220331519, Oct 20, 2022

Filed:

Apr 12, 2022

Appl. No.:

17/718663

Inventors:

- Acton MA, US
Yibin ZHENG - Hartland WI, US
Jason O'CONNOR - Acton MA, US
Ashutosh ZADE - San Diego CA, US

International Classification:

A61M 5/172
A61B 5/145
A61B 5/1495
A61M 5/142
G16H 40/40

Abstract:

Exemplary embodiments may compensate for loss of calibration by sensors that provide sensed analyte measurements to delivery devices. The exemplary embodiments may obtain one or more calibrated analyte measurements, such as by using techniques to obtain that the analyte measurement value that are known to produce properly calibrated analyte values. The one or more calibrated analyte measurements are compared to a recent analyte measurement to determine a negative or positive offset. The offset may be added to the recent analyte measurement to generate an updated analyte measurement that reflects the calibrated analyte measurement. In addition, past analyte measurement values within a time window may be updated as well by adding the offset to the past analyte measurement values. The exemplary embodiments may also compensate for the past over-delivery or under-delivery of an agent by the delivery device due to the loss of calibration.

US Patent:

20220331520, Oct 20, 2022

Filed:

Apr 19, 2022

Appl. No.:

17/723778

Inventors:

- Acton MA, US
Yibin Zheng - Hartland WI, US
Jason O'Connor - Acton MA, US

International Classification:

A61M 5/172
A61M 5/142

Abstract:

Disclosed are a system, a device, processes, techniques and computer-readable media that set an insulin adjustment factor that is applied to a dose of a therapeutic exogenous substance. The adjustment factor accounts for production of endogenous insulin related to the therapeutic exogenous substance. A processor of an automatic drug delivery device may determine and administer the doses of the therapeutic exogenous substance according to a process in which an amount of a therapeutic exogenous substance to deliver is estimated. An insulin adjustment factor utilizing an estimated relative therapeutic exogenous substance concentration may be determined. The processor may calculate a compensating dose of the therapeutic exogenous substance based on the estimated amount of the therapeutic exogenous substance to deliver that is modified by the insulin adjustment factor. The compensating dose of the therapeutic exogenous substance may be expelled from a reservoir by a pump mechanism.

US Patent:

20220288300, Sep 15, 2022

Filed:

May 25, 2021

Appl. No.:

17/330115

Inventors:

- Acton MA, US
Yibin ZHENG - Hartland WI, US
Jason O'CONNOR - Acton MA, US
Trang LY - Concord MA, US

International Classification:

A61M 5/142
G06Q 30/02

Abstract:

The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).

US Patent:

20220288311, Sep 15, 2022

Filed:

Mar 7, 2022

Appl. No.:

17/687808

Inventors:

- Acton MA, US
Yibin ZHENG - Hartland WI, US
Jason O'CONNOR - Acton MA, US

International Classification:

A61M 5/172
A61B 5/145
A61B 5/00
G16H 20/17

Abstract:

Exemplary embodiments may modify the cost function parameters based on current and projected mean outcomes in blood glucose level control performance. The exemplary embodiments may modify the weight coefficient R for the insulin cost so that the value of R is not fixed and is not based solely on clinical determined values. Exemplary embodiments may also adjust the cost function to address persistent low-level blood glucose level excursions for users. The exemplary embodiments may reduce the penalty of the insulin cost by the sum of the converted insulin cost of the glucose excursions above target for a period divided by a number of cycles of average insulin action time. The AID system reduces the insulin cost by the lack of insulin in previous cycles.

US Patent:

20220293234, Sep 15, 2022

Filed:

Mar 10, 2022

Appl. No.:

17/691829

Inventors:

- Acton MA, US
Eric BENJAMIN - Cambridge MA, US
Jason O'CONNOR - Acton MA, US
Yibin ZHENG - Hartland WI, US

International Classification:

G16H 20/13
A61M 5/172

Abstract:

The exemplary embodiments may modify a glucose cost component of the cost function of the control loop of an insulin delivery device to compensate for persistent positive low level glucose excursions relative to a target glucose level. The exemplary embodiments may enable use of different glucose cost component functions for different glucose levels of the user. These glucose cost component functions may be employed in piecewise fashion with a different piece being applied for each respective range of glucose level values for the user. The final glucose cost function for calculating the glucose cost component may be a weighted combination of a piecewise glucose cost function and a weighted standard cost function (such as a quadratic function). The weights may reflect the magnitude and/or persistence of glucose excursions relative to a target glucose level.

US Patent:

20220280721, Sep 8, 2022

Filed:

Mar 2, 2022

Appl. No.:

17/684652

Inventors:

- Acton MA, US
Yibin ZHENG - Hartland WI, US
Jason O'CONNOR - Acton MA, US

International Classification:

A61M 5/172
G16H 20/17

Abstract:

Exemplary embodiments provide more customized basal insulin amounts for users to better regulate blood glucose (BG) concentration levels. The exemplary embodiments do not statically assume that the daily basal amount for each user is 50% of TDI. Instead, actual TDI data may be gathered for each user and may be used to adjust the TDI value for that user to an updated value. In addition, the ratio of basal to TDI may be adjusted for the user based on the actual ratio determined from data gathered over one or more days. As a result, better BG concentration level control may be realized.